ClinicalTrials.gg
CompletedNCT03940586Updated Aug 22, 2024Results posted

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

A Phase 2 interventional study of Letermovir oral granules and Letermovir tablet in Cytomegalovirus (CMV) Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 40 sites in 11 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.

Enrollment
10th of 17
65 · median 80
Started
2019
with 3 others
Phase 2
4 of 17
1 open now
Registered
3rd of 17
by date
Lead sponsor
4 of 17
Merck Sharp & Dohme LLC

Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 10th largest by enrollment, is one of 4 that started in 2019, is one of 4 in phase 2, and was the 3rd registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About letermovir

letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letermovir in Cytomegalovirus Infections, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the pharmacokinetics (PK) of letermovir (LET) in pediatric participants. Participants will be enrolled in the following 3 age groups: Age Group 1: From 12 to \<18 years of age (adolescents); Age Group 2: From 2 to \<12 years of age (children); and Age Group 3: From birth to \<2 years of age (neonates, infants and toddlers). All participants will receive open label LET for 14 weeks (\~100 days) post-transplant, with doses based on body weight and age.

03

Conditions studied

  • Cytomegalovirus (CMV) Infection
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants 12 to \<18 years old must have documented positive CMV serostatus (CMV IgG seropositive) for the recipient (R+) within 90 days prior to enrollment. Participants from birth to \<12 years old must have documented positive CMV serostatus (CMV IgG seropositive) for the recipient (R+) within 90 days prior to enrollment and/or the donor (D+); the donor serostatus should be documented within 1 year prior to enrollment.
  • Is the recipient of a first HSCT (bone marrow, peripheral blood stem cell, or cord blood transplant).
  • Has undetectable CMV DNA from a plasma or whole blood sample collected within 5 days prior to enrollment.
  • Is within 28 days post-HSCT at the time of enrollment.
  • Females are not pregnant, not breastfeeding,and is not a woman of (WOCBP); or is a WOCBP who agrees to follow the guidance during the treatment period and for at least 28 days after the last dose of study intervention.
  • Participants from 2 to \<18 years of age must not be on concomitant Cyclosporin A (CsA), and must be able to take LET tablets or the oral granules (either by mouth or via G tube/NG tube), provided the participant does not have a condition that may interfere with the absorption of oral medication (e.g. vomiting, diarrhea, or a malabsorptive condition) from the day of enrollment until the intensive PK sampling is completed in these participants.
  • For participants 2 \<12 years old their weight should be at least 10 kg; for participants from birth to \<2 years old their weight should be at least 2.5 kg and less than or equal to 15 kg at the time of enrollment.

Exclusion criteria

Exclusion Criteria:

  • Has received a previous HSCT (Note: receipt of a previous autologous HSCT is acceptable).
  • Has a history of CMV end-organ disease within 6 months prior to enrollment.
  • Has evidence of CMV viremia at any time from either signing of the ICF or the HSCT procedure, whichever is earlier, until the time of enrollment.
  • Has suspected or known to active or inactive ingredients of LET formulations.
  • Has severe hepatic insufficiency within 5 days prior to enrollment.
  • Is a) on renal replacement therapy (eg, hemodialysis, peritoneal dialysis) OR b) has end-stage renal impairment.
  • Has both moderate hepatic insufficiency and moderate-to-severe renal insufficiency.
  • Has an uncontrolled infection on the day of enrollment.
  • Requires mechanical ventilation or is hemodynamically unstable at the time of enrollment.
  • Has a documented positive result for a antibody (HIVAb) test at any time prior to enrollment, or for virus antibody (HCV-Ab) with detectable HCV RNA, or surface antigen (HBsAg) within 90 days prior to enrollment.
  • Has active solid tumor with the exception of localized basal cell or squamous cell skin cancer or the condition under treatment (e.g. lymphomas).
  • Has a preexisting cardiac condition a) for which the patient is currently being treated or b) which required hospitalization within the last 6 months or c) that may be expected to recur during the course of the trial.
  • Has received within 7 days prior to screening any of the following: ganciclovir; valganciclovir; foscarnet; acyclovir; valacyclovir; famciclovir.
  • Has received within 30 days prior to screening of any of the following: cidofovir; CMV immunoglobulin; any CMV antiviral agent/biologic therapy; Rifampin and other strong inducers (such as phenytoin, carbamazepine, St John's wort (Hypericum perforatum), rifabutin and phenobarbital) and moderate inducers such as nafcillin, thioridazine, modafinil and bosentan.
  • Has received LET at any time prior to enrollment in this study.
  • Is currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5X half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing in this study.
  • Has previously participated in this study or any other study involving LET.
  • Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study.
  • Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through 28 days after the last dose of study intervention.
  • Is expecting to donate eggs starting from the time of consent through 28 days after the last dose of study intervention.
  • Has drug or alcohol abuse within 12 months of screening that may interfere with participant treatment, assessment, or compliance with the protocol, as assessed by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Letermovir

    Letermovir administered either orally or intravenously within 28 days post-transplant, once daily through week 14 (approximately 100 days). Dosing will vary based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.

    Drug: Letermovir oral granules · Drug: Letermovir tablet · Drug: Letermovir intravenous

Interventions

  • Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.

    Also known as: MK-8228, AIC246, AIC001

  • Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.

    Also known as: MK-8228, AIC246, AIC001

  • Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.

    Also known as: MK-8228, AIC246, AIC001

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years

    Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  2. AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years

    Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  3. AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages <2 Years

    Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  4. Maximal Concentration (Cmax) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years

    Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  5. Cmax of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years

    Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  6. Cmax of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years

    Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  7. Minimum Concentration of Plasma Letermovir Observed Before Next Dose (Ctrough) Taken as Oral Formulation by Ages 2 - <18 Years

    Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: 24 hours post-dose

  8. Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years

    Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  9. Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years

    Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

    Time frame: Day 7: 24 hours post-dose

  10. AUC0-24 of Plasma Letermovir Taken as Intravenous (IV) Formulation by Ages 12 - <18 Years

    Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  11. AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

    Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  12. AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

    Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  13. AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages <2 Years

    Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  14. Concentration at the End of Infusion (Ceoi) of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years

    Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model .Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  15. Ceoi of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

    Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  16. Ceoi of Plasma Letermovir Taken as IV Formulation by Ages s 2 to <12 Years

    Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. A measure of dispersion is not determined when N \<2.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  17. Ceoi of Plasma Letermovir Taken as IV Formulation by Ages <2 Years

    Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. A measure of dispersion is not determined when N \<2.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  18. Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years

    Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: 24 hours post-dose

  19. Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

    Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

    Time frame: Day 7: 24 hours post-dose

  20. Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

    Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  21. Ctrough of Plasma Letermovir Taken as IV Formulation by Ages <2 Years

    Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure type is Geometric Mean, and a measure of dispersion is not determined when N \<2.

    Time frame: Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose

  22. Ctrough of Plasma Letermovir Taken During Sparse PK for Oral Formulation

    Blood was collected on treatment Day 7 in order to determine the Ctrough of plasma letermovir during sparse PK for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant.

    Time frame: Day 7: 24 hours post-dose

  23. Ctrough of Plasma Letermovir Taken During Sparse PK as IV Formulation

    Blood was collected on treatment Day 7 in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation during sparse PK. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant.

    Time frame: Day 7: 24 hours post-dose

Secondary outcomes

  1. Percentage of Participants With One or More Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The 95% confidence interval (CI) is based on the exact binomial method proposed by Clopper and Pearson.

    Time frame: Up to Week 48 post-transplant (up to 52 weeks)

  2. Percentage of Participants Who Discontinued Study Medication Due to an AE.

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The 95% CI is based on the exact binomial method proposed by Clopper and Pearson.

    Time frame: Up to Week 14 post-transplant (up to 18 weeks)

  3. Percentage of Participants With Clinically Significant CMV Infection Through Week 14 Post-transplant

    Clinically significant cytomegalovirus (CMV) infection is defined as CMV end organ disease (proven or probable) or initiation of pre-emptive therapy (PET) based on documented CMV viremia and the clinical condition of the participant. The 95% confidence interval (CI) was based on the exact binomial method proposed by Clopper and Pearson. Missing values: were handled by the Non-Completer=Failure (NC=F) approach. where failure was defined as all participants who developed clinically significant CMV infection or prematurely discontinued from the study or had a missing outcome through week 14 post-transplant visit window.

    Time frame: Up to Week 14 post-transplant (up to 18 weeks)

  4. Percentage of Participants With Clinically Significant CMV Infection Through Week 24 Post-transplant

    Clinically significant CMV infection is defined as CMV end organ disease (proven or probable) or initiation of PET based on documented CMV viremia and the clinical condition of the participant. The 95% confidence interval (CI) was based on the exact binomial method proposed by Clopper and Pearson. Missing values: were handled by the Non-Completer=Failure (NC=F) approach. where failure was defined as all participants who developed clinically significant CMV infection or prematurely discontinued from the study or had a missing outcome through week 24 post-transplant visit window.

    Time frame: Up to Week 24 post-transplant (up to 28 weeks)

  5. Number of Participants Receiving Oral Granules With Palatability Response, Based on Taste of Medication on the First Day of Administration of Oral Formulation

    Palatability was measured by response to a questionnaire on the taste of medication , with responses from very good, good, neither good nor bad, bad or very bad.

    Time frame: Day 1 of administration of oral formulation up to Week 14 post-transplant (up to 18 weeks)

  6. Number of Participants Receiving Oral Granules With Palatability Response, Based on Taste of Medication on the Eighth Day of Administration of Oral Formulation

    Palatability was measured by response to a questionnaire on the taste of medication , with responses from very good, good, neither good nor bad, bad or very bad.

    Time frame: Day 8 of administration of oral formulation up to Week 14 post-transplant (up to 18 weeks)

07

Results

Posted Jan 30, 2024

Participant flow

Male and female recipients of a first allogeneic hematopoietic stem cell transplant (HSCT), between the ages of birth and \<18 years of age, who were at risk for cytomegalovirus (CMV) infection and/or disease, and who had undetectable CMV deoxyribonucleic acid (DNA) collected within 5 days before enrollment. were enrolled in this study.

Participant flow — Overall Study
Milestone12 - <18 Years2 - <12 YearsBirth - <2 Years
Started28298
Treated28278
Completed21216
Not completed782
Withdrew: Death320
Withdrew: Physician decision101
Withdrew: Withdrawal by parent/guardian341
Withdrew: Not treated020

Outcome measures

PrimaryArea Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years

Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Geometric mean · hr*ng/mL
Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years
hr*ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years80300 ± 74.962900 ± 37.4—
PrimaryAUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years

Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Geometric mean · hr*ng/mL
AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years
hr*ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years—39500 (23900 to 65200)—
PrimaryAUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages <2 Years

Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the AUC0-24 of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Number · hr*ng/mL
AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages <2 Years
hr*ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
AUC0-24 of Plasma Letermovir Taken as Oral Formulation by Ages <2 Years——26200
PrimaryMaximal Concentration (Cmax) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years

Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Geometric least squares mean · ng/mL
Maximal Concentration (Cmax) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Maximal Concentration (Cmax) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years7410 ± 70.110800 ± 17.4—
PrimaryCmax of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years

Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Cmax of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Cmax of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years—5500 (5430 to 5580)—
PrimaryCmax of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years

Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Cmax of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Number · ng/mL
Cmax of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Cmax of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years——2950
PrimaryMinimum Concentration of Plasma Letermovir Observed Before Next Dose (Ctrough) Taken as Oral Formulation by Ages 2 - <18 Years

Blood was collected on treatment Day 7 from participants aged 2 - \<18 years in order to determine the Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: 24 hours post-dose
Reported as:
Geometric least squares mean · ng/mL
Minimum Concentration of Plasma Letermovir Observed Before Next Dose (Ctrough) Taken as Oral Formulation by Ages 2 - <18 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Minimum Concentration of Plasma Letermovir Observed Before Next Dose (Ctrough) Taken as Oral Formulation by Ages 2 - <18 Years845 ± 107.5171 ± 2046.8—
PrimaryCtrough of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years

Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \<2 and \>12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages 2 to <12 Years—481 (207 to 1120)—
PrimaryCtrough of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years

Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged 2 - \<18 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

Time frame:
Day 7: 24 hours post-dose
Reported as:
Number · ng/mL
Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Ctrough of Plasma Letermovir Taken as Oral Formulation by Ages < 2 Years——61.7
PrimaryAUC0-24 of Plasma Letermovir Taken as Intravenous (IV) Formulation by Ages 12 - <18 Years

Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Geometric mean · hr*ng/mL
AUC0-24 of Plasma Letermovir Taken as Intravenous (IV) Formulation by Ages 12 - <18 Years
hr*ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
AUC0-24 of Plasma Letermovir Taken as Intravenous (IV) Formulation by Ages 12 - <18 Years114000 ± 37.8——
PrimaryAUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Geometric mean · hr*ng/mL
AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
hr*ng/mL12 - <18 Years2 - <12 Years, ≥30 kg BW2 - <12 Years, 18 to <30 kg BWBirth - <2 Years
AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years—36200 (21000 to 62100)31500 (20300 to 48900)—
PrimaryAUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Number · hr*ng/mL
AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
hr*ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years—25300—
PrimaryAUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages <2 Years

Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the AUC0-24 of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Number · hr*ng/mL
AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages <2 Years
hr*ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
AUC0-24 of Plasma Letermovir Taken as IV Formulation by Ages <2 Years——37300
PrimaryConcentration at the End of Infusion (Ceoi) of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years

Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model .Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Concentration at the End of Infusion (Ceoi) of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Concentration at the End of Infusion (Ceoi) of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years30600 ± 16.4——
PrimaryCeoi of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Ceoi of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
ng/mL12 - <18 Years2 - <12 Years, ≥30 kg BW2 - <12 Years, 18 to <30 kg BWBirth - <2 Years
Ceoi of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years—16800 (14900 to 19000)8200 (7580 to 8870)—
PrimaryCeoi of Plasma Letermovir Taken as IV Formulation by Ages s 2 to <12 Years

Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. A measure of dispersion is not determined when N \<2.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Number · ng/mL
Ceoi of Plasma Letermovir Taken as IV Formulation by Ages s 2 to <12 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Ceoi of Plasma Letermovir Taken as IV Formulation by Ages s 2 to <12 Years—8630—
PrimaryCeoi of Plasma Letermovir Taken as IV Formulation by Ages <2 Years

Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ceoi of plasma letermovir for participants receiving IV formulation. As samples were collected outside the collection window Ceoi for these samples were predicted by using a log linear model. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. A measure of dispersion is not determined when N \<2.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Number · ng/mL
Ceoi of Plasma Letermovir Taken as IV Formulation by Ages <2 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Ceoi of Plasma Letermovir Taken as IV Formulation by Ages <2 Years——11700
PrimaryCtrough of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years

Blood was collected on treatment Day 7 from participants aged 12 - \<18 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 12 - <18 Years709 ± 256.8——
PrimaryCtrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

Blood was collected on treatment Day 7 from participants aged 2 to \<12 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \< 2 years and \> 12 years were not presented as their data analysis resulted in a different measure type and method of dispersion.

Time frame:
Day 7: 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
ng/mL12 - <18 Years2 - <12 Years, ≥30 kg BW2 - <12 Years,18 to <30 kg BWBirth - <2 Years
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years—71.6 (12.9 to 397)318 (134 to 754)—
PrimaryCtrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years

Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure of dispersion is not determined when N \<2.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Number · ng/mL
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages 2 to <12 Years—216—
PrimaryCtrough of Plasma Letermovir Taken as IV Formulation by Ages <2 Years

Blood was collected on treatment Day 7 from participants aged \<2 years in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant. Participants aged \> 2 years were not presented as their data analysis resulted in a different measure type and method of dispersion. The measure type is Geometric Mean, and a measure of dispersion is not determined when N \<2.

Time frame:
Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose
Reported as:
Number · ng/mL
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages <2 Years
ng/mL12 - <18 Years2 - <12 YearsBirth - <2 Years
Ctrough of Plasma Letermovir Taken as IV Formulation by Ages <2 Years——98.3
PrimaryCtrough of Plasma Letermovir Taken During Sparse PK for Oral Formulation

Blood was collected on treatment Day 7 in order to determine the Ctrough of plasma letermovir during sparse PK for participants receiving oral formulation. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant.

Time frame:
Day 7: 24 hours post-dose

No measurements were reported for this outcome.

PrimaryCtrough of Plasma Letermovir Taken During Sparse PK as IV Formulation

Blood was collected on treatment Day 7 in order to determine the Ctrough of plasma letermovir for participants receiving IV formulation during sparse PK. Individual values were natural log transformed and evaluated separately with a linear mixed effects model containing a fixed effect for treatment and a random effect for participant.

Time frame:
Day 7: 24 hours post-dose

No measurements were reported for this outcome.

SecondaryPercentage of Participants With One or More Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The 95% confidence interval (CI) is based on the exact binomial method proposed by Clopper and Pearson.

Time frame:
Up to Week 48 post-transplant (up to 52 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Adverse Event (AE)
Percentage of participants12 - <18 Years2 - <12 YearsBirth - <2 Years
Percentage of Participants With One or More Adverse Event (AE)100.0 (87.7 to 100.0)100.0 (87.7 to 100.0)100.0 (63.1 to 100.0)
SecondaryPercentage of Participants Who Discontinued Study Medication Due to an AE.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The 95% CI is based on the exact binomial method proposed by Clopper and Pearson.

Time frame:
Up to Week 14 post-transplant (up to 18 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Medication Due to an AE.
Percentage of participants12 - <18 Years2 - <12 YearsBirth - <2 Years
Percentage of Participants Who Discontinued Study Medication Due to an AE.17.9 (6.1 to 36.9)7.4 (0.9 to 24.3)12.5 (0.3 to 52.7)
SecondaryPercentage of Participants With Clinically Significant CMV Infection Through Week 14 Post-transplant

Clinically significant cytomegalovirus (CMV) infection is defined as CMV end organ disease (proven or probable) or initiation of pre-emptive therapy (PET) based on documented CMV viremia and the clinical condition of the participant. The 95% confidence interval (CI) was based on the exact binomial method proposed by Clopper and Pearson. Missing values: were handled by the Non-Completer=Failure (NC=F) approach. where failure was defined as all participants who developed clinically significant CMV infection or prematurely discontinued from the study or had a missing outcome through week 14 post-transplant visit window.

Time frame:
Up to Week 14 post-transplant (up to 18 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant CMV Infection Through Week 14 Post-transplant
Percentage of participants12 - <18 Years2 - <12 YearsBirth - <2 Years
Percentage of Participants With Clinically Significant CMV Infection Through Week 14 Post-transplant20.0 (6.8 to 40.7)16.7 (4.7 to 37.4)28.5 (3.7 to 71.0)
SecondaryPercentage of Participants With Clinically Significant CMV Infection Through Week 24 Post-transplant

Clinically significant CMV infection is defined as CMV end organ disease (proven or probable) or initiation of PET based on documented CMV viremia and the clinical condition of the participant. The 95% confidence interval (CI) was based on the exact binomial method proposed by Clopper and Pearson. Missing values: were handled by the Non-Completer=Failure (NC=F) approach. where failure was defined as all participants who developed clinically significant CMV infection or prematurely discontinued from the study or had a missing outcome through week 24 post-transplant visit window.

Time frame:
Up to Week 24 post-transplant (up to 28 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant CMV Infection Through Week 24 Post-transplant
Percentage of participants12 - <18 Years2 - <12 YearsBirth - <2 Years
Percentage of Participants With Clinically Significant CMV Infection Through Week 24 Post-transplant24.0 (9.4 to 45.1)25.0 (9.8 to 46.7)28.6 (3.7 to 71.0)
SecondaryNumber of Participants Receiving Oral Granules With Palatability Response, Based on Taste of Medication on the First Day of Administration of Oral Formulation

Palatability was measured by response to a questionnaire on the taste of medication , with responses from very good, good, neither good nor bad, bad or very bad.

Time frame:
Day 1 of administration of oral formulation up to Week 14 post-transplant (up to 18 weeks)
Reported as:
Count of participants · Participants
Number of Participants Receiving Oral Granules With Palatability Response, Based on Taste of Medication on the First Day of Administration of Oral Formulation
Participants12 - <18 Years2 - <12 YearsBirth - <2 Years
Very good030
Good153
Neither good nor bad181
Bad183
Very bad130
SecondaryNumber of Participants Receiving Oral Granules With Palatability Response, Based on Taste of Medication on the Eighth Day of Administration of Oral Formulation

Palatability was measured by response to a questionnaire on the taste of medication , with responses from very good, good, neither good nor bad, bad or very bad.

Time frame:
Day 8 of administration of oral formulation up to Week 14 post-transplant (up to 18 weeks)
Reported as:
Count of participants · Participants
Number of Participants Receiving Oral Granules With Palatability Response, Based on Taste of Medication on the Eighth Day of Administration of Oral Formulation
Participants12 - <18 Years2 - <12 YearsBirth - <2 Years
Very good030
Good143
Neither good nor bad184
Bad050
Very bad030

Adverse events

Collected over All-cause mortality (ACM): from allocation/randomization (i.e. prior to treatment) up to Week 48 post-transplant (up to 52 weeks). AEs: From first treatment up to Week 48 post-transplant (up to 52 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
12 - <18 Years4/28 (14.3%)13/28 (46.4%)27/28 (96.4%)
2 - <12 Years2/29 (6.9%)18/27 (66.7%)27/27 (100%)
<2 Years0/8 (0%)7/8 (87.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
Event12 - <18 Years2 - <12 Years<2 Years
Epstein-Barr virus infection reactivationInfections and infestations0/280/272/8
Secondary adrenocortical insufficiencyEndocrine disorders0/280/271/8
Acute graft versus host diseaseImmune system disorders0/280/271/8
Graft versus host diseaseImmune system disorders1/281/271/8
BacteraemiaInfections and infestations0/281/271/8
Cytomegalovirus infection reactivationInfections and infestations1/280/271/8
Device related infectionInfections and infestations0/280/271/8
Epstein-Barr virus test positiveInvestigations0/280/271/8
NeurotoxicityNervous system disorders0/280/271/8
Venoocclusive diseaseVascular disorders0/280/271/8
Most frequent other events
Showing 10 of 115
Most frequent other events
Event12 - <18 Years2 - <12 Years<2 Years
VomitingGastrointestinal disorders17/2821/274/8
DiarrhoeaGastrointestinal disorders14/2813/271/8
PyrexiaGeneral disorders11/2813/274/8
NauseaGastrointestinal disorders12/288/270/8
ThrombocytopeniaBlood and lymphatic system disorders5/2811/270/8
Abdominal painGastrointestinal disorders11/287/271/8
Graft versus host diseaseImmune system disorders10/2810/273/8
HypertensionVascular disorders8/2810/270/8
NeutropeniaBlood and lymphatic system disorders2/289/271/8
StomatitisGastrointestinal disorders9/289/270/8

Baseline characteristics

Treated Participants

Age, Continuous
Age, Continuous(Years)12 - <18 Years2 - <12 YearsBirth - <2 YearsTotal
Mean14.1 ± 1.56.6 ± 3.20.7 ± 0.39.1 ± 5.3
Sex: Female, Male
Sex: Female, Male(Participants)12 - <18 Years2 - <12 YearsBirth - <2 YearsTotal
Female135119
Male1522744
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)12 - <18 Years2 - <12 YearsBirth - <2 YearsTotal
Hispanic or Latino94114
Not Hispanic or Latino1421641
Unknown or Not Reported5218
Race (NIH/OMB)
Race (NIH/OMB)(Participants)12 - <18 Years2 - <12 YearsBirth - <2 YearsTotal
American Indian or Alaska Native0000
Asian6309
Native Hawaiian or Other Pacific Islander0000
Black or African American3003
White1522744
More than one race4217
Unknown or Not Reported0000
08

Study locations

40 sites
  • City of Hope Comprehensive Cancer Center ( Site 0251)
    Duarte, California 91010, United States
  • Children's Hospital of Orange County ( Site 0241)
    Orange, California 92868, United States
  • UCSF Benioff Children's Hospital San Francisco ( Site 0245)
    San Francisco, California 94158, United States
  • University Of Chicago School Of Medicine ( Site 0253)
    Chicago, Illinois 60637, United States
  • Boston Children's Hospital ( Site 0243)
    Boston, Massachusetts 02115-5737, United States
  • Memorial Sloan Kettering Cancer Center ( Site 0254)
    New York, New York 10065, United States
  • Duke University Health System ( Site 0252)
    Durham, North Carolina 27705, United States
  • Cincinnati Children's Hospital Medical Center ( Site 0244)
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Pittsburgh of UPMC ( Site 0258)
    Pittsburgh, Pennsylvania 15224, United States
  • Children's Medical Center ( Site 0257)
    Dallas, Texas 75235, United States
  • Seattle Childrens Hospital ( Site 0248)
    Seattle, Washington 98105, United States
  • The Children s Hospital at Westmead ( Site 0185)
    Westmead, New South Wales 2145, Australia
  • Lady Cilento Children s Hospital ( Site 0182)
    South Brisbane, Queensland 4101, Australia
  • Royal Childrens Hospital Melbourne ( Site 0181)
    Parkville, Victoria 3052, Australia
  • Instituto De Cancerologia S.A. ( Site 0213)
    Medellin, Antioquia 050024, Colombia
  • Fundacion Valle del Lili ( Site 0212)
    Cali, Valle Del Cauca 760032, Colombia
  • Centro Medico Imbanaco de Cali S.A ( Site 0211)
    Cali, Valle Del Cauca 760042, Colombia
  • Hôpital Universitaire Necker Enfants Malades-, Unite d'Immunologie-Hematologie et Rhumatologie Pedi
    Paris, 75015, France
  • Universitaetsklinikum Frankfurt ( Site 0112)
    Frankfurt, Hessen 60590, Germany
  • Universitaetsklinikum Muenster ( Site 0114)
    Muenster, Nordrhein-Westfalen 48149, Germany
  • Charite Universitaetsmedizin Berlin - Campus-Virchow-Klinikum ( Site 0113)
    Berlin, 13353, Germany
  • Universitatsklinikum Hamburg-Eppendorf ( Site 0111)
    Hamburg, 20246, Germany
  • Rambam Medical Center ( Site 0121)
    Haifa, 3109601, Israel
  • Schneider Children's Medical Center ( Site 0122)
    Petah Tikva, 4920235, Israel
  • Pediatric Hemato Oncology Safra Children's Hospital, Sheba Medical Center ( Site 0123)
    Ramat Gan, 5265601, Israel
  • Saitama Children's Medical Center ( Site 0202)
    Saitama, 330-8777, Japan
  • National Center for Child Health and Development ( Site 0201)
    Tokyo, 157-8535, Japan
  • Instituto Nacional de Pediatria ( Site 0224)
    Mexico City, Distrito Federal 04530, Mexico
  • Hospital Infantil de Mexico ( Site 0221)
    Mexico City, Distrito Federal 06720, Mexico
  • Nuevo Hospital Civil Dr Juan I Menchaca ( Site 0223)
    Guadalajara, Jalisco 44340, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez" ( Site 0222)
    Monterrey, Nuevo Leon 64460, Mexico
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckieg-Klinika Transplantacji Szpiku, Onkolog
    Wrocław, Dolnoslaskie 50-556, Poland
  • Szpital Uniwersytecki nr 1 im. Dr. Antoniego Jurasza w Bydgoszczy ( Site 0141)
    Bydgoszcz, Kujawsko-pomorskie 85-094, Poland
  • H. de la Santa Creu I Sant Pau ( Site 0155)
    Barcelona, 08025, Spain
  • Hospital Universitari Vall d Hebron ( Site 0154)
    Barcelona, 08035, Spain
  • Hospital Infantil Universitario Nino Jesus ( Site 0151)
    Madrid, 28009, Spain
  • Hospital Universitario La Paz ( Site 0153)
    Madrid, 28046, Spain
  • Acibadem Adana Hastanesi ( Site 0162)
    Adana, 01130, Turkey
  • Akdeniz University Faculty of Medicine ( Site 0161)
    Antalya, 07070, Turkey
  • Ege Univ.Tip Fakultesi Cocuk Has ( Site 0163)
    Izmir, 35040, Turkey
09

References and documents

Publications

  • Groll AH, Schulte JH, Antmen AB, Fraser CJ, Teal VL, Haber B, Caro L, McCrea JB, Fancourt C, Patel M, Menzel K, Badshah C. Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients. Pediatr Infect Dis J. 2024 Mar 1;43(3):203-208. doi: 10.1097/INF.0000000000004208. Epub 2024 Jan 19. PubMed 38241643 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jan 2023, 40 months.

Results were first posted in Jan 2024, 1 year after primary completion.

Of 29 phase 2 interventional studies under Cytomegalovirus Infections, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 62. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2019
First posted
May 7, 2019
StartActual
Aug 8, 2019
Primary completionActual
Jan 4, 2023
CompletionActual
Aug 25, 2023
Results first posted
Jan 30, 2024
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03940586
Responsible party
Sponsor
First posted
May 7, 2019
Start date
Aug 8, 2019
Primary completion
Jan 4, 2023
Completion
Aug 25, 2023
Results posted
Jan 30, 2024
Last update
Aug 22, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion